header logo image


Page 1,082«..1020..1,0811,0821,0831,084..1,0901,100..»

Unique opportunity to get your arthritis worries addressed – Starts at 60

March 17th, 2017 7:41 am

Despite the fact that millions of Australians are affected by arthritis, theres still much we dont know about the condition.

While we know sufferers often suffersevere pain and even disfigurement, there are still unanswered questions that have left many in the dark about living with arthritis, as well as the possibility of a cure.

This is no small issue: almost 4million Australians live with arthritis a number thats expected to blow out to 7 million by 2050 and another 6.3 million have low bone density, a related condition.

Now, a public seminar offers peoplerare opportunity to ask doctors and arthritis experts questions about the condition and have them answered in a thorough, thoughtful way.

In a bid to open up theconversation about the common but poorly understood condition, the Queensland University of Technology is hosting a public seminar on Saturday 18 March, where anyone can come along and listen to experts talk about the latest innovations in this area. The seminar, which is part of of QUTs Real World Health series, will be held in Brisbane and broadcast live online so people around the country can tune in and take part.

Themost pressing issues in arthritis research is the need to develop an early-diagnosis test, and to find acure for the condition. Professor Yin Xiao from the QUT Institute of Health and Biomedical Innovation is working on just that.

At present theres no single test which will early diagnose or a drug that cure osteoarthritis, he told Starts at 60. In particular, our research interests include identifying risk factors of osteoarthritis, evaluating new ways of early diagnostics through improved imaging methods, and working towards designing and testing new treatments that help to repair osteoarthritis joints.

At the seminar, speakers will be addressing key questions, including:

The experts will openthe floor to the public to pose questions, and those who cant attend in person canemail questions through ahead of time thenwatch the seminar via a live stream online from home.

If youd like to submit a question about arthritis, you can do by emailing [emailprotected] before Saturday.

See more here:
Unique opportunity to get your arthritis worries addressed - Starts at 60

Read More...

3 Women Blinded After Stem Cell Therapy – Newser

March 17th, 2017 7:40 am

Newser
3 Women Blinded After Stem Cell Therapy
Newser
CORRECTS FROM MD ANDERSON HOSPITAL TO MD ANDERSON CANCER CENTER -Senior Clinical Cell Therapy Specialist Megan Raggio prepares stem cells from bone marrow before they are transplanted into sportscaster... (AP Photo/David J. Phillip).
One stem cell treatment stabilizes macular degeneration, another blinds 3 patientsCNN
Doctors say stem cell treatment at clinic blinded 3 womenWABC-TV
Three women blinded after stem cell injections at Broward clinicMiami Herald
Science Magazine -NPR -Stanford Medical Center Report -The New England Journal of Medicine
all 126 news articles »

See the rest here:
3 Women Blinded After Stem Cell Therapy - Newser

Read More...

Stem Cell Therapy | Runner’s World – Runner’s World

March 17th, 2017 7:40 am

Runner's World

Excerpt from:
Stem Cell Therapy | Runner's World - Runner's World

Read More...

New Cardiac Stem Cell Therapy passes Phase I/II Trials – Labiotech.eu (blog)

March 17th, 2017 7:40 am

TiGenix announces positiveone-year results forits phase I/II trial of donor-derived cardiac stem cell therapy in acute myocardial infarction (AMI).

The Belgian biotech TiGenixis developing allogeneic stem cell therapies. Now the companyhasannouncedthat its cardiac stem cell therapyAlloCSC-01 reached its primary endpoints in aphase I/IItrial.

In 2015, the companyacquired Coretherapixin a292M deal for its allogeneic cardiac stem cell pipeline, which is being developed for the treatment of AMI.The first-in-human trial was designed to test the safety and feasibility of an intracoronary infusion of donor-derivedexpanded cardiac stem cells (AlloCSCs)in patients with AMI and left ventricular dysfunction.

AlloCSC-01consists of adult allogeneic cardiac stem cells isolated from the heartof donors and expanded in vitro. In vivo studies suggest that these cellshave cardio-reparative potential by activating regenerative pathways and promoting the formation of new hearttissue.

Thecurrent phase II study demonstrated thesafety of these allogeneic stem cells. Initial results also revealed a larger reduction of infarct size in a subgroup of patients.

Myocardial infarction caused by blockade of coronary arteries

TiGenix is well known forChondroCellect, which was the first cell therapyto reach the European market for the repair of knee cartilage.After the companyrecently withdrew its market authorization for this product, due to a lack of reimbursement, the biotech is focusing on another stem cell therapy, Cx601, in addition to AlloCSC-01. Under development for Crohns disease, Cx601 is currently awaitingEMA approval and is in phase III trials in the US.

For a late-stage clinical company, TiGenix has a low market cap of191M. Even so, the company seems to be doing well these days with the progress of Cx601 and AlloCSC-01.

If AlloCSC-01 obtains market approval, it could treat the more than 1.9 millionpeople affected by AMI, a major cause of heart failure. So far, most treatments are palliative or restore myocardial function by angioplasty and insertion of a stent to support the vascular lumen.

Stem cell therapy of the heart is definitely not a new topic, but many trials have been conducted using the patients own stem cells derived from the bone marrow. A recent meta-analysisof such trials has suggested that these therapies are safe, but do not enhance cardiac function. TiGenixs approach using allogeneic heart-derived stem cells may offer a new and promisingopportunity in thefield.

Images via shutterstock.com / Liya Graphics andVeronika Zakharova

View original post here:
New Cardiac Stem Cell Therapy passes Phase I/II Trials - Labiotech.eu (blog)

Read More...

Unproven stem cell therapy causes three women to go blind – Times LIVE

March 17th, 2017 7:40 am

The women, aged between 72 and 88, were treated in Florida in 2015 for a progressive eye disease called macular degeneration, said the report in the New England Journal of Medicine.

They thought they were enrolling in a legitimate clinical trial, having found it under the title: "Study to assess the safety and effects of cells injected intravitreal in dry macular degeneration" on ClinicalTrials.gov, the US government website for such research.

However, they immediately suffered complications, including retinal detachment and hemorrhage, which caused total loss of eyesight.

The clinic and patients involved were not named in the study, which was co-authored by Thomas Albini, associate professor of clinical ophthalmology at the University of Miami.

Two of the patients sought treatment at the university's hospital for the complications they suffered.

"There's a lot of hope for stem cells, and these types of clinics appeal to patients desperate for care who hope that stem cells are going to be the answer," said Albini.

"But in this case these women participated in a clinical enterprise that was off-the-charts dangerous."

The procedure claimed to use adipose-derived stem cells to restore vision.

Patients had fat cells removed from their abdomens. This fat tissue was processed with enzymes in order to get stem cells, which would be mixed with platelet-dense plasma and injected into their eyes.

Albini said the complications could have been caused by contamination during the mixing process, or the stem cells, once injected into the eye, could have changed into a type of cell that led to scarring.

Whatever happened, experts said there was no evidence to suggest the procedure would have helped restore vision, since so little study has been done on whether adipose-derived stem cells can mature into the kinds of retinal cells that are involved in macular degeneration.

"Reading this article gives me chills down my spine," said Nazanin Barzideh, chief of vitreoretinal surgery at Winthrop University Hospital in Mineola, New York, who was not involved in the study.

"There were so many red flags," she told AFP.

Among them, the patients received injections in both eyes at the same time, when more responsible physicians would have tried one first to see how the patient reacted to the procedure before doing the other eye.

"You do not do a bilateral injection in the same setting," she said.

Also, the patients were asked to pay $5,000 each for the procedure, which is a signal of fraud since clinical trials do not charge patients to participate.

"There is also no basic evidence for this trial," she said, urging patients to always seek a second opinion from a medical professional before agreeing to any therapy.

Another outside expert, Sung Chul Park, director of the Glaucoma Clinic at Manhattan Eye, Ear and Throat Hospital, agreed.

"These cases emphasize the importance of evidence-based medicine in patient care," he said.

Co-author Jeffrey Goldberg, professor and chair of ophthalmology at the Stanford University School of Medicine, described the report as a "call to awareness for patients, physicians and regulatory agencies of the risks of this kind of minimally regulated, patient-funded research."

The US Food and Drug Administration has since released more specific guidelines requiring regulatory oversight and approval for these types of procedures.

Clinical trials can be confusing, so Goldberg recommended patients search online for "A Closer Look at Stem Cells," by the International Society for Stem Cell Research, for more information.

"Although numerous stem cell therapies for medical disorders are being investigated at research institutions with appropriate regulatory oversight, many stem cell clinics are treating patients with little oversight and with no proof of efficacy," said the study.

See the rest here:
Unproven stem cell therapy causes three women to go blind - Times LIVE

Read More...

These Women Went Blind After A Florida Clinic Injected Fat Cells Into Their Eyeballs – BuzzFeed News

March 16th, 2017 12:43 am

Lixia Guo / BuzzFeed News

ID: 10708849

Elizabeth Noble enjoyed a full and active life, and is nobodys fool. For more than a quarter-century, she taught statistics in the School of Education at the University of Missouri-Kansas City. In retirement, she continued to work as a consultant, and travelled widely in Europe and Asia.

When Noble was diagnosed with Age-Related Macular Degeneration, which slowly blurs the sharp central vision that we rely on to read, drive, and identify faces, she wanted to do something about it. And she thought she had found an answer a research study described on ClinicalTrials.gov, a website run by the National Institutes of Health (NIH), the US governments premier biomedical research agency.

It seemed scientifically legitimate, so in June 2015 Noble went to a clinic in Sunrise, Florida, where staff sucked a small quantity of fat from around her belly button, treated it with enzymes to extract the cells it contained, and mixed those cells with a sample of Nobles blood plasma. They injected the mixture into Nobles eyeballs, charged her $5,000, and told her to avoid strenuous activity for the next three days.

US Stem Cell Clinics office in Sunrise, Florida. Google Street View

ID: 10705938

Three days later, when the 72-year-old was seen by doctors at the University of Miamis Bascom Palmer Eye Institute, strenuous activity was out of the question. Nobles eyes hurt and she was nauseous. Her retinas were bleeding and she could just make out a hand being waved in front of her face.

Nobles sight continued to deteriorate and one year later she couldnt tell the difference between night and day. Thats as bad as it gets, Thomas Albini, an ophthalmologist at the Bascom Palmer Eye Institute, told BuzzFeed News, describing the condition of the woman he identified only as Patient 1.

In the latest issue of the New England Journal of Medicine, Albini and his colleagues describe the cases of three women treated by the same stem cell company, each of whom became legally blind. The doctors dont name the women involved, but BuzzFeed News established the identities of two of them from court filings and other public documents.

This isnt the first time that people have been harmed by clinics offering unproven treatments purportedly involving stem cells. In 2010, for example, a woman with the autoimmune disease lupus died after her own bone marrow cells were injected into her kidneys at a clinic in Thailand. And in 2013, the Florida Department of Health revoked the medical license of Zannos Grekos over the death of a 69-year-old woman. He had extracted material from her bone marrow, filtered it, and then infused it into the arteries feeding her brain. The woman had a stroke, and died shortly afterwards.

But the latest tragic cautionary tale has a disturbing twist, as two of the women who were blinded contacted the company involved, now called US Stem Cells but formerly known as Bioheart, only after reading about its macular degeneration study on ClinicalTrials.gov.

The site was launched in 2000 after Congress passed a law demanding that the NIH keep a registry of clinical trials experiments with new drugs on volunteer patients so that drug companies couldnt sweep negative results under the carpet. ClinicalTrials.gov has since grown to include some 290,000 studies run in countries across the globe.

But with only minimal screening of the listings, experts who track the burgeoning and loosely regulated landscape of stem cell clinics fear that the website is being abused to claim spurious legitimacy for unproven therapies that are being sold for profit.

Its very easy to register studies on ClinicalTrials.gov and essentially use a government website as a marketing device, Leigh Turner, a bioethicist at the University of Minnesota, told BuzzFeed News.

Noble told the doctors at the Bascom Palmer Eye Institute that she thought her treatment was part of a clinical trial. Patients are not usually charged to take part in research. Yet each of the three women described in the case reports were charged $5,000, and Albini said that the consent paperwork made no mention of a study.

I think it was presented as a clinical trial and documented as a fee-for-service procedure, Albini said. In September 2015, shortly after the three women were treated, the ClinicalTrials.gov listing was amended to say the study had been withdrawn prior to enrollment.

Before that change was made, it is easy to see why Noble and Patsy Bade, who also decided to seek treatment after finding the ClinicalTrials.gov listing, might have found it convincing. It includes an long list of conditions that could exclude people from participating, and indicates that patients would be studied 6 months after their treatment, to record their field of view and the sharpness of their vision.

Neither Noble nor Bade had severe sight loss before their eyeballs were injected with material extracted from their abdominal fat. Noble still had 20/30 vision in her left eye, which is barely different from normal. Its good enough to read newspaper print, Albini said. Its very functional vision. Bade, who was 78 when she was treated and lives in Venice, Florida, struggled to read fine print and had problems driving at night. But otherwise, she could function normally.

The back of Patsy Bades left eye after the stem cell treatment. Dark patches show bleeding in the retina. Thomas Albini

ID: 10705950

These ladies who were both independent were rendered blind, their attorney, Andrew Yaffa of Grossman Roth Yaffa Cohen in Coral Gables, Florida, told BuzzFeed News. The women sued US Stem Cell, the affiliated US Stem Cell Clinic, and two medical professionals who were involved in the procedures.

The suits were settled for undisclosed sums, with a confidentiality agreement that prevents Yaffa from naming the women or the company involved. Noble and Bade also told BuzzFeed News that they were not allowed to discuss their cases.

This litigation has been resolved to the mutual satisfaction of the parties, Yaffa said.

A couple of days after her injections, Bade turned up at the Bascom Palmer Eye Institute with bleeding retinas. Again, her eyesight rapidly deteriorated. A year later, she could just detect a hand waving in front of her face with her right eye, and had 20/200 vision in her left. That is the legal threshold for blindness, and means she could read an eye chart at 20 feet only as well as a person with normal vision standing 200 feet away.

Both womens eyesight would likely still be fairly good had they not been given the injections. Macular degeneration typically proceeds pretty slowly, Albini said.

Neither Mike Toms, US Stem Cells CEO, nor Kristin Comella, the companys chief science officer, returned emails and phone calls from BuzzFeed News. Comella is described on the companys website as a world renowned expert on regenerative medicine. She is not a medical doctor, and is enrolled as a PhD student in biomedical engineering at Florida International University in Miami.

Kristin Comella, US Stem Cells chief science officer, in a promotional video. youtube.com

ID: 10708284

The company responded instead with a statement from its PR firm, Becker Public Relations, which said: Since 2001, our clinics have successfully conducted more than 7,000 stem cell procedures with less than 0.01% adverse reactions reported. We are unable to comment further on specific cases due to patient confidentiality or legal confidentiality obligations. Neither US Stem Cell nor US Stem Cell Clinic currently treats eye patients.

On its website, US Stem Cell Clinic says it offers treatments for conditions from Parkinsons disease to congestive heart failure. US Stem Cells PR company would not say how many of the 7,000 procedures the company claims to have performed involved patients with eye diseases.

While the blinding of three patients is an extreme example, experts who follow the stem cell industry worry that other people may have been harmed by clinics offering unproven treatments, without their cases coming to public attention.

What Im most worried about is that this may be the tip of the iceberg, Paul Knoepfler, a stem cell biologist at the University of California, Davis, told Buzzfeed News. Last year, he and Turner of the University of Minnesota published a survey that identified 570 clinics offering unproven stem-cell treatments across the US.

Most of these clinics argue that their treatments do not need to be regulated by the Food and Drug Administration (FDA) because they are merely injecting peoples own stem cells back into their bodies. The FDA maintains that these cells count as drugs, which it must approve for clinical use, if they are more than minimally manipulated and are not replacing cells with the same basic function.

Last September, the FDA held a two-day hearing on treatments based on human cells. The FDA is evaluating the feedback we received at the hearing, along with the written comments, as we work to finalize our guidance, agency spokesperson Andrea Fischer told BuzzFeed News by email.

Its unclear whether that will to lead to a crackdown on clinics offering unproven stem-cell treatments especially as President Donald Trumps nominee for FDA commissioner, Scott Gottlieb, in 2012 co-wrote an Op-Ed for the Wall Street Journal criticizing the agencys efforts to regulate cells as drugs.

The FDA is perennially complaining to Congress that it lacks the resources to do its day job of regulating products that fall squarely in its purview, Gottlieb and his co-author wrote. Yet in chorus, the agency is always seeking novel authority to insert itself into new areas of science where its mandate is shaky.

Whatever the FDA does next, Turner argues that the NIH should do more to screen the listings posted on ClinicalTrials.gov.

The information on ClinicalTrials.gov is provided by the study sponsor or principal investigator and posting on ClinicalTrials.gov does not necessarily reflect endorsement by the NIH, Renate Myles, an NIH spokeswoman, told BuzzFeed News by email.

Earlier today, the NIH added a similarly-worded disclaimer to the website. Myles said that the change was made because of the concerns raised by Alibinis paper.

It is time NIH representatives stopped giving boilerplate responses, Turner said. They should have addressed this problem before patients were harmed.

Go here to read the rest:
These Women Went Blind After A Florida Clinic Injected Fat Cells Into Their Eyeballs - BuzzFeed News

Read More...

Model of anorexia nervosa created using stem cells – Science Daily

March 16th, 2017 12:43 am

An international research team, led by scientists at University of California San Diego School of Medicine, has created the first cellular model of anorexia nervosa (AN), reprogramming induced pluripotent stem cells (iPSCs) derived from adolescent females with the eating disorder.

Writing in the March 14th issue of Translational Psychiatry, the scientists said the resulting AN neurons -- the disease in a dish -- revealed a novel gene that appears to contribute to AN pathophysiology, buttressing the idea that AN has a strong genetic factor. The proof-of-concept approach, they said, provides a new tool to investigate the elusive and largely unknown molecular and cellular mechanisms underlying the disease.

"Anorexia is a very complicated, multifactorial neurodevelopmental disorder," said Alysson Muotri, PhD, professor in the UC San Diego School of Medicine departments of Pediatrics and Cellular and Molecular Medicine, director of the UC San Diego Stem Cell Program and a member of the Sanford Consortium for Regenerative Medicine. "It has proved to be a very difficult disease to study, let alone treat. We don't actually have good experimental models for eating disorders. In fact, there are no treatments to reverse AN symptoms."

Primarily affecting young female adolescents between ages 15 and 19, AN is characterized by distorted body image and self-imposed food restriction to the point of emaciation or death. It has the highest mortality rate among psychiatric conditions. For females between 15 and 24 years old who suffer from AN, the mortality rate associated with the illness is 12 times higher than the death rate of all other causes of death.

Though often viewed as a non-biological disorder, new research suggests 50 to 75 percent of risk for AN may be heritable; with predisposition driven primarily by genetics and not, as sometimes presumed, by vanity, poor parenting or factors related to specific groups of individuals.

But little is actually known about the molecular, cellular or genetic elements or genesis of AN. In their study, Muotri and colleagues at UC San Diego and in Brazil, Australia and Thailand, took skin cells from four females with AN and four healthy controls, generated iPSCs (stem cells with the ability to become many types of cells) from these cells and induce these iPSCs to become neurons.

(Previously, Muotri and colleagues had created stem cell-derived neuronal models of autism and Williams syndrome, a rare genetic neurological condition.)

Then they performed unbiased comprehensive whole transcriptome and pathway analyses to determine not just which genes were being expressed or activated in AN neurons, but which genes or transcripts (bits of RNA used in cellular messaging) might be associated with causing or advancing the disease process.

No predicted differences in neurotransmitter levels were observed, the researchers said, but they did note disruption in the Tachykinin receptor 1 (TACR1) gene. Tachykinins are neuropeptides or proteins expressed throughout the nervous and immune systems, where they participate in many cellular and physiological processes and have been linked to multiple diseases, including chronic inflammation, cancer, infection and affective and addictive disorders.

The scientists posit that disruption of the tachykinin system may contribute to AN before other phenotypes or observed characteristics become obvious, but said further studies employing larger patient cohorts are necessary.

"But more to the point, this work helps make that possible," said Muotri. "It's a novel technological advance in the field of eating disorders, which impacts millions of people. These findings transform our ability to study how genetic variations alter brain molecular pathways and cellular networks to change risk of AN -- and perhaps our ability to create new therapies."

Story Source:

Materials provided by University of California - San Diego. Original written by Scott LaFee. Note: Content may be edited for style and length.

See more here:
Model of anorexia nervosa created using stem cells - Science Daily

Read More...

Is Alzheimer’s treatment of injecting stem cells into the brain a breakthrough or quackery? – San Angelo Standard Times

March 16th, 2017 12:43 am

Keith Sharon, The Orange County Register (TNS) 9:56 p.m. CT March 15, 2017

Jack Sage has been receiving an experimental treatment where a doctor injects stem cells into his brain to treat his Alzheimer's disease.(Photo: Paul Rodriguez, TNS)

IRVINE, Calif. More than eight years after he realized something was wrong, after, as he described it, My brain went

Whats the word? Foggy, Jack Sage finally said after several seconds of silently coaxing his synapses to fire.

More than eight years after his brain went foggy, four years after he was diagnosed with Alzheimers disease and two years since he began an innovative and extremely invasive therapy, Sage said he is being flooded by memories that seem new, or, at the very least, feel easier to retrieve. His daughter, Kate, thought Sage had suddenly begun to open up about his past because he knew his time was growing short.

He should not know who I am at this point, Kate said.

His doctor, Christopher Duma, hopes Jack Sage goes down in history as the one-man turning point in the treatment of Alzheimers disease, while others are skeptical about what Duma has done to Sages brain. Everyone agrees that Alzheimers disease is an exploding problem.

The California Alzheimers Disease Data Report from 2009 projected a 67 percent increase between 2015 and 2030 in residents in Los Angeles, Orange, Riverside and San Bernardino counties living with Alzheimers disease up to 498,137. The same report references a study, between 2000 and 2004, in which 58 percent of the deaths among people 65 and older in California were attributed to Alzheimers disease.

The Alzheimers Association reported that 610,000 Californians 65 or older had the disease in 2016, and it estimated increases to 690,000 by 2020 and 840,000 by 2025.

On a cool recent night, Sage, a handsome, fit, 82-year-old, sat next to his wife Gloria talking about his children (It is significant that Sage remembers their names James, 46, Kate, 50, and Kelly, 56), recalling when he and Gloria moved into the Newport Beach house with a view of the Pacific Ocean (1990), laughing about their first date at the Bel-Air Country Club (1979), recounting his years as a labor negotiator and executive for Del Monte, Allied Chemical and Continental Airlines (1970s and 60s) and going all the way back to the jack hammering he did in the nickel mines (mid-1950s) in Northern Ontario, Canada.

At this point in his illness, his doctor said he should be having more trouble remembering the perilous tunnels of the Sudbury nickel mine.

You drill into the granite, Sage said. You put dynamite in the rock. You dynamite it. Then you shovel out whats left.

And mining, you might say, is what is happening in Jack Sages brain.

Dr. Christopher stands in front of an MRI of Jack Sage's brain on Feb. 28, 2017 at his office in Irvine, Calif. Duma conducted phase one of clinical trials on a new treatment for Alzheimer's disease called intra-cerebro ventricular injection of autologous mesenchymal stem cells. He basically took fat cells from Jack Sage's body, spun them down to stem cells and then injected them back in to Sage's brain.(Photo: Jeff Gritchen, TNS)

Sages series of recollections, including his exploits on the golf course in Indian Wells where he has a second home and plays several days a week flashbacks representing the three main components of long-term memory: semantic (recalling the meaning of words), episodic (recalling autobiographic milestones) and procedural (recalling how to accomplish tasks) prompted a grin from Duma, the brain surgeon who, for $10,000 per treatment and without insurance coverage, cut a hole in the back of Sages head and injected a stem cell serum that had been sucked out of Sages love handles.

Is this the Alzheimers breakthrough the world has been waiting for? Or, is this unproven medical procedure what University of Minnesota bioethicist Leigh Turner calls quackery and flimflam? Is this an unsafe, money-grab it is being conducted outside the approval process of the Food and Drug Administration preying on the most vulnerable among us?

Turner has written extensively and critically about the Cell Surgical Network (CSN), for which Duma, whose home hospital is Hoag in Newport Beach, is listed as a network physician. The CSN promotes the stem cell revolution, which its literature claims, is an appropriate treatment for people suffering from a variety of inflammatory and degenerative conditions in other words, for cancer, diabetes, bad knees and hips as well as multiple uses in cosmetic surgery.

You dont just start dumping things into peoples brains, Turner said. The problem is people may spend a lot of money and find there is no benefit. He (Duma) is exposing people to serious harm. Fat cells dont belong in peoples brains.

Sage is the first patient in Phase I of a clinical study officially called Intracerebroventricular injection of autologous abdominal fat-derived, non-genetically altered stem cells. Sage was the first Alzheimers patient anywhere to have his own liposuctioned cells injected directly into his brain. He has received eight injections (about two months apart) since November 2014.

Duma quickly offers a qualifier. It is far too early to tell if what he has done to Sage will indeed change the world. He said Sage and, later, 19 other patients have not been harmed by the procedure, and that safety is the only criteria in Phase I. Whether the treatment is effective is a question for Phase II, for which Duma is hoping to attract private funding. Also, he wrote a letter to the national Alzheimers Association asking for $700,000 to continue his work. He was instructed to apply officially later this year. If he gets the grant, the fees for his patients would be waived.

Early in the process, Duma is excited by Sages results.

Sages most recent cognition scores have risen from 45 on the 100-point Memory Performance Index in March 2015 to 54 in September 2015. The volume of his hippocampus the memory center of the brain has grown from the fifth percentile before his first treatment to the 28th percentile after his fourth treatment to the 48th percentile after his eighth treatment.

My golf game is getting better, said Sage, who, heart permitting, plays several times per week. Sages brain isnt his only problem. He has a long history of heart ailments that have required the insertion of 12 stents to keep his arteries open.

You cant make a global conclusion based on one patient, but its a huge turning point, Duma said with the confidence of someone who probes brains for a living.

Duma is somewhat of a maverick in the medical world, a brain surgeon who regularly shuns a scalpel for the gamma knife, a futuristic laser for removing brain tumors. He is known outside the operating room for playing keyboards in bands that specialize in 1970s-era covers of groups such as Genesis, Yes and Emerson, Lake and Palmer. As a child, he was a classmate of John F. Kennedy Jr. at The Browning School in New York City. We called him John John, Duma said.

Duma realizes he will face opposition to his stem cell/brain injection therapy. But, as in all breakthroughs, someone has to be first.

I could have harmed people, he said. I took an enormous leap.

Alzheimers patients dont get better.

They get diagnosed, lose their dignity and die.

The speed at which death occurs is the only variable.

In the depressing world of Alzheimers treatment, Sage and Duma represent equal parts hope and skepticism. The Orange County Register contacted universities and research centers across the country, including Stanford, Harvard, Duke, Florida International, UC Davis, and some of the interview requests were denied while other calls were not returned. Very few medical experts want to talk about the combination of stem cells and Alzheimers disease, apparently because they know so little about it.

An Alzheimers patient improving because of therapy? Im hopeful its true. Im hopeful its true for all patients, said Joshua Grill, the co-director of the Memory Impairments Neurological Disorders (MIND) institute at UC Irvine. We are in dire need.

Jack Sage and his wife Gloria react in January to the positive results of Jack's latest MRI from Dr. Christopher Duma, left, at their home in Corona del Mar, Calif. More than eight years after his brain went foggy, four years after he was diagnosed with Alzheimer's disease and two years since he began an innovative and extremely invasive therapy, Sage said he is being flooded by memories that seem new, or, at the very least, feel easier to retrieve.(Photo: Paul Rodriguez, TNS)

But, Grill continued, One study does not a revolution make. Ive never read anything about this (Dumas work), and I dont know what science is behind it.

Dean Hartley, Director of Science Initiatives at the Alzheimers Association, knew about Dumas work.

This is new territory, Hartley said. But with one patient, No, you cannot say this is a game-changer.

Hartley said many studies fail at the Phase II level, where more and more people are exposed to the therapy.

Still, Hartley said Dumas work is encouraging.

We want to see things like this happen, Hartley said.

Its not as if Duma is conducting his research in secret. He spoke about his study in public forums twice last year Sept. 28 at the Congress of Neurological Surgeons in San Diego, and Oct. 1 at the International Society for Cellular Therapy in Memphis.

Duma said he is nearly finished writing a paper about his work that he hopes will be published in a peer-reviewed journal.

In 1993, Christopher Duma was working at Good Samaritan Hospital in Los Angeles when he and his colleagues began injecting stem cells into the brains of patients with Parkinsons disease. They were making some progress, he said, but politics intervened. Some of the stem cells they were using came from aborted fetuses. Pressure from anti-abortion groups shut that program down.

Fifteen years later, Duma was assisting plastic surgeon Michael Elam on a face-lift on a Parkinsons patient when Elam said, We need to talk about stem cells.

Elam introduced Duma to Drs. Mark Berman and Elliot Lander, the founders of the Cell Surgical Network.

Berman and Lander had been separating stem cells from fat by using a centrifuge (which they own the patent for) and injecting them into knees and hips and other places where injuries had occurred. Their work had passed an Institutional Review Board after 1,524 patients were treated with no adverse effects, Berman said.

If you want to repair an injury, Berman said, the best tissue is the stem cell.

In 2013, Duma suggested a new target for stem cell therapy: the brain.

Duma, with Berman, Lander and Elam as co-authors, tried to begin a study of brain/stem cell injections. But their first attempt at Institutional Review Board approval was denied because they hadnt done animal testing. So they got Dr. Oleg Kopyov at Cal State Northridge to conduct tests on rats.

With the help of Kopyovs work, Duma got Institutional Review Board approval. They chose not to take the usual next step FDA approval.

The Institutional Review Board was expecting us to go through the FDA, Lander said. But there are hundreds of obstructions. The FDA approval process usually takes between eight and 12 years, according to the online journal Medscape.com.

Duma said stem cells present a quandary for the FDA because stem cells are not a drug, and theyre not food. Clinics that take stem cells out of the body and put them back in without additives argue that they are exempt from FDA mandates.

We have been harvesting fat from abdomens and putting them in the brain during brain surgeries since the 1920s, Duma said. We do it nearly on every case for pituitary tumors, acoustic and skull base tumors and for conditions of spinal fluid leakage since the 1920s. If the FDA ruled that harvested autologous fat cannot be used in the brain, then it would change nearly a century of neurosurgical standard of care.

Someday, Duma said he hopes the FDA will recognize his work.

The work cant wait, he said.

Jack Sage and his wife Gloria at their home in Corona del Mar in January.(Photo: Paul Rodriguez, TNS)

In August 2013, Jack Sage staggered into the office of Dr. William Shankle in Newport Beach.

Shankle, a renowned expert in cognitive disease he is the author of the Memory Performance Index that is used around the world diagnosed Sage with two problems: Alzheimers disease and hydrocephalus (fluid on the brain). Sage needed a shunt in his brain to drain the fluid and relieve the pressure.

So Shankle walked him down the hall (their offices are yards apart on the same floor in the same building) and introduced Sage to Christopher Duma, medical director of Hoag Hospitals Brain Tumor Program, and the surgeon who would put in the shunt.

Duma remembers that first meeting. Sage was in straight-line cognitive decline, Duma said.

Shankle would not grant an interview about Duma or his treatment. Shankle said he is wary of hocus pocus about Alzheimers disease without saying that Duma has done anything wrong. More than a decade ago, Shankle tried a surgical stem cell therapy on patients. He removed patients stem-cell-rich omentum, a fatty sheath covering the abdomen, cut open their skulls and stretched the omentum directly on their brain. Four of the six patients he studied had serious complications from the surgery.

The patients improved in cognitive tests, but the surgery was too much for them.

The method of delivering the treatment was radical (surgical transposition of the greater omentum to the surface of the brain while keeping the blood supply intact), Shankle wrote in an email. After showing that it really works, my goal was to never do the surgery again but find a different way of delivering these critical factors less invasively.

Sage was the patient Duma had been waiting for.

Jack was a man who was doomed, Duma said. He looked like classic Alzheimers. He had no ability to follow a train of thought. He was asking and re-asking the same questions. People like Jack are there, but theyre not there.

Sage was perfect for Duma for other reasons. He has always been a fitness nut cycling, tennis, golf, skiing and 10K runs were all part of his lifestyle. Kate Sage said he has been ordering salmon and spinach for dinner at restaurants for years.

Jack is the experimental model, Duma said. He is the brave one.

During two years of treatments, Sage has either maintained or slightly improved his cognitive health. He had a major heart attack in 2016, making his brain less of a cause for concern than his heart.

Kate said she doesnt know if Dumas treatment is working.

Its hard for me to say this is miraculous, Kate said.

She said she doesnt worry about his brain as much anymore.

Hes going to drop dead with some kind of a heart thing, she said. Hes not going to lose his memory.

Jack Sage passed his written test recently to renew his driver's license.(Photo: Paul Rodriguez, TNS)

The tragedy of Alzheimers disease is that it not only steals the history that makes us who we are. It takes our skills, our beliefs, our independence, our ability to love.

So far, Jack Sage is still Jack Sage. Obviously, he doesnt know if he would be the same without Dumas treatments.

I can tell Im getting better and better, Sage said. Is that pure optimism? The Placebo Effect?

In January, Jack Sages drivers license came up for renewal. He said hes able to remember driving directions without problem. He still navigates the route from his home in Newport Beach to his other home in Indian Wells. But, he was required to pass the written test, and Sage feared he wouldnt be able to remember the complex rules of the road.

I was worried, he said.

But he passed, and his license was extended five years.

His improved memory, he said, sometimes catches him by surprise.

These memories come up when I dont even think about it, Sage said.

Sometimes, the memories take Sage places he doesnt want to go.

When he worked in the nickel mines in the 1950s, he and his first wife had a son.

His name was Mark, Sage said, speaking slowly as if the memory was bubbling up from depths he didnt want to consider. We rented a house with a playroom. My wife went shopping, and I was upstairs

I was working on my school work for McMaster University

Mark fell

we had a drainage basin inside the house

when I got to him, he was gone

Sage stopped talking as if flooded by new emotions over the death of his son.

We were distraught, he said. It was tough times for years.

In the murky world of Alzheimers therapy, Jack Sage is still mining.

Read or Share this story: http://www.gosanangelo.com/story/life/wellness/2017/03/15/alzheimers-treatment-injecting-stem-cells-into-brain-breakthrough-quackery/99240794/

Read the original here:
Is Alzheimer's treatment of injecting stem cells into the brain a breakthrough or quackery? - San Angelo Standard Times

Read More...

Common Joins See America In The Fight Against Preventable Blindness – Look To The Stars

March 16th, 2017 12:43 am

See America, Allergans initiative to fight against preventable blindness in the United States, today unveiled a powerful video featuring award-winning actor and hip-hop artist Common, that urges Americans to stand in the way of darkness.

The video harnesses Commons striking spoken word ability, calling on Americans to fight against vision loss and prioritize their vision. Common highlights the 61 million Americans at-risk of severe vision loss, and challenges us all to imagine a life without sight.

Im proud to join Allergan in the fight against preventable blindness, said Common. Sight is something that far too many of us take for granted. I hope our message resonates with people across the country, no matter what age or background.

Commons involvement echoes the mission of Allergans See America initiative by raising awareness to make sure that each and every one of us makes the time to prioritize our vision. Taking steps as simple as regular comprehensive eye exams can help detect eye diseases like glaucoma, diabetic retinopathy or age-related macular degeneration early, before irreversible damage is done.

On Commons partnership with See America, We are excited to have joined forces with Common to raise awareness of the important issue of preventable blindness in America. This video marks the first of many ways in which we aim to educate and engage the public. Common shares our bold approach to life, and we believe that this video will take us one step closer to nationwide appreciation for the gift of sight, said Herm Cukier, Allergan Senior Vice President of Eye Care.

To watch the video, and to learn more about See America, visit http://www.SeeAmerica.vision.

Visit link:
Common Joins See America In The Fight Against Preventable Blindness - Look To The Stars

Read More...

WEDNESDAY WOMAN: Faith despite blindness – Nation News

March 16th, 2017 12:43 am

Diana Applewhite believes her faith in God will see her sight restored someday. (Picture by Ricardo Leacock)

During March, the Month Of The Disabled, the Wednesday Woman column will focus on people with disabilities.

DIANA APPLEWHITE went blind overnight.

SHE WENT TO SLEEP being able to see, but the next morning her sight was completely gone, changing her life completely.

It happened July 1, 2009, she said. I will never forget that date. I went to bed early because I was having a bad headache and the Sunday morning I woke up my usual time to prepare for church, but I thought outside was very dark. I turned on the light and it was still dark so I thought the electricity was off.

Even after she went for her cell and could not seethe mobile phone light, she was puzzled but did not think of the worst.

I was not thinking about loss of eyesight, nothing like that, she said. I do not know how to describe the feeling I felt in words; it was like someone knocked all the breath out of my lungs. I just fell to the floor rolling bout hollering and crying.

Yet, Applewhite, who is diabetic, said she always knew of the risk of blindness as a result of diabetic retinopathy, which is caused by high blood sugar levels damaging the back of the eye (retina).

Because she had the condition, she always went for her opticians appointment which showed that everything was normal on each occasion.

Eight years on, Applewhite has found it hard to accept the loss of her sight and believes that God can restore it if He so chooses.

Full acceptance, no; I believe my eyesight will be restored in Jesus name, she said.

Going back to that Sunday when I was rushed to the hospital and they did the tests, they were saying you will never see again. That is one conversation I will never forget as long I live; (the doctor) just ran off this long list of things I would never be able to do again; like if he was the hammer and I was the nail and he was driving the message home. I felt so bad then, that all I could do was cry, but now I know I serve a living God and in all things I give thanks.

Applewhite said the part that kerfuffled herwas that there were no symptoms or anything to indicate an eyesight problem. She ate what she considered a healthy diet and always went for medical check-ups.

Adjusting was the hardest part, she said.The first two years I cried every single day andgetting to wrap my mind around the idea of doing things differently. I have a daughter and a son.My daughter was eight years at the time and shewas a real trooper; she stepped up and helped me make the adjustment.

Applewhite and her daughter, as young asshe was, created a series of hand signals to aidmobility. For instance, they would walk holdinghands and if her daughter kept her hand flat, itwas flat road, when her hand dipped it meant tostep down and if it went up it meant to step upand so on. So when they were out in public, Applewhite did not have to use a cane.

Mother and daughter would also put little bumps on the washing machine, microwave and push-button telephone so that Applewhite would still be able to use household appliances. Everything in the house has remained in the same position to allow her to get around with no issues.

She had access to disability trainingwith the National Disabilities Unit a few months after her vision loss, but by then, shewas already gettingby, thanks to herdaughter.

Cannot and never are some of the words that Applewhite chooses to keep out of her vocabulary. Because of her disability, people tend to say she cannot do certain things, but she is determined always to show them how wrong they are.

She still goes totown, to the hospitaland doctor on her ownand is living life as normally as she can.

She said her dayshave not changed much; the only thing she cannot do is read, but she still cooks, washes, cleans, takes the bus and doesher own shopping.

Applewhite hasbecome very active in the Barbados National Organisation of the Disabled (BARNOD)and now serves as chairperson of education and public relations officer. They say I talk a lot, Applewhite said witha laugh.

She serves onseveral other committees that keep her busy and active. In fact she isbusier than when shehad a job.

Applewhite said she likes to push awareness of disabilities and when any new information is announced, she puts it in the public domain.

When we keep the public informed then people do not have to be saying, oh I dont know how to deal with them. They realise that we are all the same we just do things differently, she said.

One of the major changes she has seensince she lost her sight is that she has not worked since. Having worked at a major bank in sales, Applewhite said shewould like to set up her own business.

I am not ruling out having an employer completely, but I do not think I can take the humps and grumps of working for someone., she said. I am at the age where I want a more relaxed environment.

To anyone at the beginning stage of the journey towards vision loss, Applewhites advice is not to give up on life even though blindness might seem like a death sentence at first.

They can still live a full life, she said. You can do all the things you want to do; there are organisations that can help you adjust. Also, God is able and through faith, your sight can be restored.

lisaking@nationnews.com

See the original post:
WEDNESDAY WOMAN: Faith despite blindness - Nation News

Read More...

Ceramics artist inspired by nature, biotechnology – Jewish News of Greater Phoenix

March 16th, 2017 12:43 am

Ceramist Susan Beiners work has been exhibited in China, France, the Netherlands and across the nation, but it took some persuading to get her to exhibit her creations at Temple Solels latest Art Showcase.

After some cajoling, Beiner relented and now her earlier work is on display at Temple Solel through May 31. A reception and talk featuring Beiner are scheduled for 10:30 a.m. Sunday, April 2, at Temple Solel, 6805 E. McDonald Drive, Paradise Valley.

Your current subscription does not provide access to this content. Please click the button below to manage your account.

kAmp %6>A=6 $@=6= >6>36C D:?46 a_`b[ q6:?6C 😀 2? 2DD@4:2E6 AC@76DD@C 2E pC:K@?2 $E2E6 &?:G6CD:EJD[ w6C36C86C r@==686 @7 u:?6 pCE] w6C 96D:E2?4J E@ D9@H 96C H@C< 2E $@=6= 42>6 7C@> E96 724ED E92E D96 925 ?6G6C 4@?D:56C65 5:DA=2J:?8 96C 2CE 😕 2 DJ?28@8F6 367@C6[ 2D H6== 2D E96 =2C86 D:K6 @7 96C =2E6DE 4C62E:@?D]k^Am

kAm(6 E@=5 $FD2? D96 H2D 2 EC6>6?5@FD C6D@FC46 2?5 2 A2CE @7 E96 E6>A=6 2?5 H6 H2?E65 E@ D66 96C H@C<[ D2:5 xC2 %9@>2D[ 2 >6>36C @7 E96 pCE o $@=6= 4@>>:EE66] %9:D 😀 E96 7:CDE E:>6 H6G6 925 2 46C2>:4:DE]k^Am

kAmx?DA:C65 3J E96 4C27ED >@G6>6?E[ q6:?6C 3682? 4C62E:?8 9:89=J 56E2:=65[ 2?5 2E E:>6D H9:>D:42=[ E62A@ED 😕 E96 62C=J `hh_D] p=E9@F89 D96 DE:== E@@< AC:56 :? 96C E62A@ED[ 3J a__b[ q6:?6C D2:5 D96 ?66565 2 8C62E6C 2CE:DE:4 492==6?86 2?5 >@G65 @? E@ =2C86 H2== :?DE2==2E:@?D 2?5 D4F=AEFC6D]k^Am

kAmx ;FDE 5:5?E H2?E E@ >2<6 E62A@ED 2?J>@C6[ q6:?6C D2:5] x 5:5?E 766= 2D E9@F89 E96 E62A@ED H6C6 23@FE E96 7F?4E:@?2= AC@5F4E 😕 2?J H2J] x E9:?< E96J H6C6 >@C6 23@FE 2 7@C> H:E9 H9:49 E@ >2<6 >@C6 D4F=AEFC2= @C:6?E2E:@?] p7E6C x 5:5 >J 7:CDE =2C86 H2== A:646 😕 a__b[ x 76=E x 4@F=5 8@ 7FCE96C] x 4@?D:56C E96 E62A@ED 😕 2 5:776C6?E H2J E92? x 5@ >J =2E6DE H@C<] ,%96 ?6H H@C<. :D 2 5:776C6?E >:?5D6E @7 9@H x> >2<:?8 :E[ H9J x> >2<:?8 :E 2?5 E96 :562D 369:?5 :E]k^Am

kAm%96 E9:?8D x >2<6 ?@H E2<6 2 =@E =@?86C[ 3FE E96J 2C6 >@C6 @7 2 492==6?86 2?5 x E9:?< E96J 86E 36EE6C 2?5 36EE6C H:E9 E:>6[ q6:?6C 25565] x =62C? 7C@> 6249 @?6 2?5 E@ >6 E92E 😀 H@CE9 6G6CJE9:?8]k^Am

kAm{:<6 96C E62A@ED[ 96C ?6H H@C2E6C:2=D DF49 2D A=6I:8=2DD[ 7@2> 2?5 24CJ=:4D] uC@> 272C[ E96 C6DF=ED 42? =@@< =:<6 2 82C56? @7 7=@H6CD F?E:= 4=@D6C 6I2>:?2E:@? C6G62=D E96 >2?>256[ :?5FDEC:2= 2CE:7:46 E92E C6AC6D6?ED 96C :?E6C6DE 😕 ?2EFC6 2?5 3:@E649?@=@8J]k^Am

kAm*@F 42?E E6== H92ED C62= 2?5 H92ED >256 2?J>@C6[ q6:?6C D2:5] (6 42? 8C@H 2?JE9:?8 😕 E6C>D @7 v|~D W86?6E:42==J >@5:7:65 @C82?:D>DX 2?5 E9:?8D =:<6 E92E] *@F 42? 8C@H 2?J A=2?E E@ 36 D@>6E9:?8 6=D6] %96C6 2C6 2== D@CED @7 E9:?8D E92E 2C6 36:?8 5@?6 E92E >2<6 >J H@C< D66> >@C6 C62=]k^Am

kAmsF6 E@ DA246 =:>:E2E:@?D 2E %6>A=6 $@=6=[ q6:?6C 😀 >@DE=J 6I9:3:E:?8 96C 62C=J E62A@ED]k^Am

kAmq6:?6C 😀 A2CE @7 E96 E9:C5 42==E@2CE:DED 7@C E96 pCE $9@H42D6 D6C:6D 2E %6>A=6 $@=6= D:?46 a_`a] $96 😀 ;@:?65 3J D6G6? @E96C 2CE:DED H@C<:?8 :? DF49 >65:F>D 2D 24CJ=:4D[ @:=[ A9@E@8C2A9J 2?5 A2:?E:?8] %96 2CE:DED H@C< 42? 2=D@ 36 AFC492D65[ H:E9 2 A6C46?E286 @7 E96 AC@4665D 8@:?8 E@ 7F?5 2? 2CE D49@=2CD9:A 2H2C565 2??F2==J E@ 2 E6>A=6 >6>36C 9:89 D49@@= D6?:@C]k^Am

kAm(6G6 366? C62==J 3=6DD65 92G:?8 D@ >2?J %6>A=6 $@=6= >6>36CD H:E9 D@ >2?J 5:G6CD6 <:?5D @7 E2=6?ED E2=6?ED E92E D@>6 @7 E96> 5@?E 6G6? C64@8?:K6 E96>D6=G6D[ %9@>2D D2:5] |6>36CD @7 @E96C DJ?28@8F6D 92G6 G:D:E65 %6>A=6 $@=6= E@ D66 E96 G2C:@FD pCE $9@H42D6D] %9@>2D 9@A6D E92E :?E6C6DE H:== 3=@DD@> :?E@ D@>6E9:?8 3:886C]k^Am

kAm(6C6 C62==J 9@A:?8 E92E 5@H? E96 C@25 H6 42? 86E 2? 2CE 4@>>F?:EJ H:E9:? E96 #67@C> 4@?8C682E:@?D 😕 E96 '2==6J[ 96 D2:5]k^Am

Janet Perez is a freelance writer based in Phoenix.

View post:
Ceramics artist inspired by nature, biotechnology - Jewish News of Greater Phoenix

Read More...

College hires leader for Biotechnology Center of Excellence – Triad Business Journal

March 16th, 2017 12:43 am

Triad Business Journal
College hires leader for Biotechnology Center of Excellence
Triad Business Journal
Our Biotechnology Center of Excellence will be key to Alamance County's economic development and we are excited to have an administrator with the depth and breadth of experience as Yonnie Butler, said President Algie Gatewood. His range of ...

Read more:
College hires leader for Biotechnology Center of Excellence - Triad Business Journal

Read More...

Nasdaq Composite Index Approaches Record High as Biotechnology, IT Advance – Economic Calendar

March 16th, 2017 12:43 am

The Nasdaq Composite Index rose Wednesday, buoyed by broad advances at biotechnology and IT companies, after the Federal Reserve decided to raise interest rates for the second time in three meetings.

The technology-heavy index rose 0.7% to 5,900.05, its fifth advance in the last six sessions. The benchmark index settled just below all-time highs.

With the gain, the Nasdaq has returned nearly 10% for the year, outpacing the S&P 500 Index and Dow Jones Industrial Average.

A total of 2,009 companies listed on the Nasdaq reported gains, versus 888 that finished lower and 229 that went unchanged. A total of 166 companies reported new highs, versus 47 that set new lows.

Health stocks listed on the S&P 500 rose more than 1%, with pharmaceuticals, biotechnology and life sciences leading the rally. Information technology also advanced 0.6% as a sector.

Advertising

The Nasdaq Biotechnology Index rose 1.5% to 3,162.82.

The Federal Reserve raised its benchmark interest rate by a quarter point to 1% in a move that was widely anticipated by the markets. Policymakers continue to expect three rate increases this year, putting the central bank on course for two additional adjustments in 2017.

In terms of upcoming releases, the U.S. Labor Department will report on initial jobless claims on Thursday. Separately, the Commerce Department will report on housing starts and building permits. The Philadelphia Fed will also report on regional manufacturing conditions in the early morning.

See the original post:
Nasdaq Composite Index Approaches Record High as Biotechnology, IT Advance - Economic Calendar

Read More...

Sam Konduros named president and CEO of SC Biotechnology Industry Organization – Greenville News

March 16th, 2017 12:43 am

Sam Konduros(Photo: Provided)

Sam Konduros, a former executive director of Greenville Health Systems Research Development Corporation, was named on Monday as the new president and CEO of the S.C. Biotechnology Industry Organization.

SCBIO is a statewide, non-for-profit that represents and organizes innovators in medicine, medical devices and biomaterials.

Konduros is a currently a member of the SCBIO Board of Directors.

I greatlyappreciate the SCBIO boardspassion forservingand advancing South Carolinas rapidly growing life sciences community and industry sector, and for their vote of confidence in my leadership capabilities for the organization going forward, Konduros said in a statement.

Architecture and design firm adds new hire to Greenville office

Verizon looks to fill 100 positions at new telesales center in Greenville

Konduros, a business leader and biomedical and economic development consultant, is the founder of SK Strategies LLC, launched in 2004, and has led a number of state economic development efforts.

He was the founding president and CEO of theUpstate S.C. Alliance, and is a former chairman for the Greenville Chamber of Commerce and a former committee member of the S.C. Chamber of Commerce.

Konduros has a law degree from the University of South Carolina and an undergraduate degree from Clemson University. He is alsoa graduate of the Economic Development Institute at the University of Oklahoma.

Sams strengths in knowing the biotech sector and his deep experience in business and economic development were compelling, Erin Ford, chair of SCBIO, said in a statement. The board was won over by his vision for the growth of SCBIO.

Read or Share this story: http://grnol.co/2mJTIWt

Go here to read the rest:
Sam Konduros named president and CEO of SC Biotechnology Industry Organization - Greenville News

Read More...

Arthritis Limits Daily Activities of 24 Million U.S. Adults – AAFP News

March 16th, 2017 12:42 am

More than 54 million adults in the United States -- or about one in four -- have arthritis, and almost 60 percent of these individuals are of working age (i.e., ages 18-64). What's worse is that more than 24 million adults with arthritis have activity limitations from their disease, with the percentage of these patients having grown from about 36 percent in 2002 to about 43 percent in 2014.

That's according to a CDC Morbidity and Mortality Weekly Report(www.cdc.gov) (MMWR) and an accompanying Vital Signs report(www.cdc.gov) released March 7. The reports were based on data from the CDC's 2013-2015 National Health Interview Survey (NHIS).

Physical limitations these adults experience may be as simple as having difficulty holding a cup, lifting a grocery bag or walking to their car -- but they still hinder their ability to pursue everyday activities.

"Arthritis symptoms keep millions of Americans from going about their daily routines," said CDC Acting Director Anne Schuchat, M.D., in a news release.(www.cdc.gov) "Doctors and loved ones can help people with arthritis by encouraging them to be as physically active as they can be. Physical activity is a proven strategy to ease pain and reduce symptoms among people with arthritis."

The CDC found that when patients with arthritis engage in physical activity, they can reduce their arthritis symptoms by as much as 40 percent. However, many adults with arthritis aren't physically active, with about one-third reporting they don't engage in physical activity during leisure time.

The reports also noted that adults with arthritis can reduce their symptoms by participating in disease management education programs. But these programs are being underutilized, with just one in 10 patients signing up. According to the CDC, the best way to improve sign-up rates is for health care professionals to recommend these programs, because adults with arthritis are significantly more likely to attend an education program when their physician suggests they do so.

As previous NHIS survey analyses have found, women, adults who were unable to work, those in fair or poor health, and those with obesity, heart disease or diabetes had higher age-adjusted prevalences of both arthritis and arthritis-attributable activity limitations.

Although the prevalence of arthritis among adults who were unemployed was similar to that among employed adults, unemployed respondents had a much higher prevalence of arthritis-attributable activity limitations. According to the CDC, this finding suggests that disease-attributable activity limitations may play a role in these people's unemployment.

Also as in past analyses, arthritis prevalence was similar among blacks and whites, but the prevalence of arthritis-attributable activity limitations was higher among blacks. Findings in Hispanics were mixed, with a much lower prevalence of arthritis but a proportionately higher prevalence of arthritis-attributable activity limitations.

"Our findings suggest that the burden of arthritis is increasing and requires more widespread use of existing, underused evidence-based interventions," the MMWR report concluded. "Physical activity is a proven strategy for managing arthritis, with known benefits for the management of many other chronic conditions."

The report went on to say that efforts to improve the health of adults with arthritis, including those with comorbid chronic conditions, should include wider dissemination and implementation of evidence-based interventions.

"These interventions meet the unique needs of adults with arthritis and have been found to reduce pain and improve function, mood and confidence to manage health and quality of life," the report said.

Because the CDC views arthritis as a large and growing clinical and public health problem, the agency is funding arthritis programs in 12 states this year to disseminate community-based arthritis-appropriate evidence-based physical activity and self-management education interventions.

"Its extremely important for primary care providers to encourage their patients with arthritis to be physically active," said CDC epidemiologist Kamil Barbour, Ph.D., in the news release. "It is just as important for them to motivate their patients to attend workshops to learn how to better manage their arthritis."

Related AAFP News Coverage New NIH Research Program Targets Health Disparity, Chronic Disease (9/7/2016)

More From AAFP American Family Physician: AFP By Topic: Arthritis and Joint Pain

Familydoctor.org: Rheumatoid Arthritis(familydoctor.org)

Read the original here:
Arthritis Limits Daily Activities of 24 Million U.S. Adults - AAFP News

Read More...

It’s arthritis and it hurts – Buffalo Bulletin

March 16th, 2017 12:42 am

If your dog could talk, being his best friend would be a lot easier. However, he cant tell you that his knees stiffen up after he plays too long or that his hips hurt when he goes up or down stairs. Hes counting on you to recognize signs of pain and decreased mobility and to have your veterinarian diagnose and treat the condition.

Its arthritis. And it hurts.

I have it, too. Most older people do. The Pfizer Animal Health and the Arthritis Foundation have joined together the first ever partnership between a human health disease foundation and an animal health disease to explore the insights, facts and treatment solutions for both human and canine arthritis sufferers alike.

Arthritis affects over 70 million humans and 11 million dogs. It is a chronic health problem for both people and their dogs, causing pain, loss of mobility and quality of life. We know humans suffer from stiff joints, soreness and inflammation due to arthritis. Upon observation, you can see how this affects our beloved canine friends. It is up to us to help them find relief through diet, exercise and medication.

Arthritis is a painful, degenerative joint disease that affects one in five adult dogs in the U.S.

It is even more common in older dogs (my very limited experience has been that larger dogs seem to be really susceptible, too). Unfortunately, many of the cases go undiagnosed because owners attribute the subtle changes in the dogs to old age or slowing down.

Any dog can develop arthritis, and knowing the signs and symptoms of pain will help you determine when your dog may need veterinary attention. Could your dog have arthritis? Ask yourself these simple questions: Does your dog limp or appear stiff during or after activity? Is your dog slow to rise from a resting position? Does your dog lag behind or tire easily during long walks? Is your dog reluctant to climb steps or jump up?

If your answers to these questions are yes, its possible that your dog is suffering from painful arthritis. The sooner your dog is properly diagnosed and treated, the sooner he can overcome the pain. If your dog has arthritis, pain relief is possible with Rimadyl, a medication for dogs that has been proven clinically effective for the relief of pain associated with arthritis.

I dont know exactly how long Rimadyl has been on the market, but I think it has been available by prescription for a relatively short time from your veterinarian. It is a non-steroidal, anti-inflammatory medication available in caplets and in easy-to-give chewable tablets that dogs love (all dogs, except mine). Signs of Rimadyl intolerance may include loss of appetite, vomiting and diarrhea, which could indicate side effects involving the digestive tract, liver or kidneys. This sounds horrible and even worse than the illness itself. Some of these reported side effects are really rare at less than 1 percent.

Please dont let your dog suffer with the pain of arthritis.

For the animals, thank you for caring.

Originally posted here:
It's arthritis and it hurts - Buffalo Bulletin

Read More...

Canine cannabis: Dogs with anxiety, arthritis and more benefiting from products derived from hemp plant – fox6now.com

March 16th, 2017 12:42 am

fox6now.com
Canine cannabis: Dogs with anxiety, arthritis and more benefiting from products derived from hemp plant
fox6now.com
MILWAUKEE Pet owners across the country are going crazy over a hemp product they claim helps improve the health of their dogs and cats. Veterinarians are now jumping on board and recommending it to clients instead of animal pharmaceuticals.

Here is the original post:
Canine cannabis: Dogs with anxiety, arthritis and more benefiting from products derived from hemp plant - fox6now.com

Read More...

Pitt Study Sheds Light On Genetic Link Between Schizophrenia And Arthritis – 90.5 WESA

March 16th, 2017 12:42 am

Scientists have long known that there is a link between schizophrenia and rheumatoid arthritis. People who suffer from schizophrenia tend not to develop rheumatoid arthritis, and people with rheumatoid arthritis are at low risk for schizophrenia.

Though this relationship has been clear for more than 50 years, nobody really knew why the link existed, according to University of Pittsburgh professor of psychiatry and human geneticsVishwajitNimgaonkar.

We thought that there might be genetic factors that might explain this phenomenon, he said.

Nimgaonkarshunch has been backed up bynew research identifying 29 genetic markersin the human genome that are associated with both diseases.

One form of the marker increases the risk for schizophrenia and another form of the marker increases the risk for rheumatoid arthritis, he said.

A genetic marker is an individual gene or a sequence of DNA.

Nimgaonkarsaid all 29 of the markers they identified were within eight genes already thought to be possible culprits for both schizophrenia and rheumatoid arthritis.

Nimgaonkarsaid he hypothesizes that there is a complex relationship between the proteins produced by these genes and the likelihood someone might develop either disease. Genes produce proteins that carry out the genetic instructions to generate particular attributes such as hair color, height or susceptibility to specific diseases.

Probably there are thousands of genes, each of small effect, that may be together causing the risk for this illness and interacting with each other to produce the risk, said Harvard Medical School psychiatry professorMatcheriKeshivan.

KeshivansaidNimgaonkarswork is consistent with the theory that schizophrenia might have some auto-immune component, similar to rheumatoid arthritis, wherein the immune system attacks healthy joint cells.

Rheumatoid arthritis is an autoimmune disease in which the bodys immune system attacks healthy joint cells, creating inflammation, leading to pain and swelling. About 1.5 million Americans suffer from rheumatoid arthritis, which can cause permanent joint damage and disfiguring if not treated early, according to theArthritis Foundation.

Keshivansaid that in patients with schizophrenia, genes might overproduce proteins that are meant to clean up neurons in the brain, a process known as synaptic pruning, which can lead to healthy neurons being damaged.

Keshivansaid hes hopeful that better understanding of the genetic causes of schizophrenia can lead to new treatments and added that the disease is likely caused by genetic factors.

But at the same time, we do not have a very good idea as to which particular genes might be causing this disease, Keshivan said.

According to theSchizophrenia and Related Disorders Alliance of America, orSARDAA, about 3.5 million Americans and 1.1 percent of the worlds population are affected by the disease, which is characterized by delusions, hallucinations and disorganized speech and behavior.

Keshivansaid other symptoms of the disease include a lack of motivation and impaired cognition, which he called negative symptoms. He said, while treatments currently available are reasonably effective at treating the delusions and hallucinations, treating the negative symptoms is much more difficult. He said hes hopeful that understanding more about the genetic causes of the disease can lead to more holistic therapies.

SARDAAreports that about 75 percent of patients reach full or partial recovery, while a quarter do not see improvements with existing therapies, which include medication and psychotherapy.

While there are many questions left unanswered,Nimgaonkarsaid the findings represent a good starting point for further research. Because the analysis depended completely on existing datasets, he said laboratory experiments will help confirm and clarify his teams results.

What we are trying to do is to reach out to our colleagues inrheumatology, and what wed like to do is test these theories using actual tissues from patients: brain tissue, synovial (joint) tissues, or blood cells, he said.

The findings are published in the journalnpjSchizophrenia.

Photo Credit: Timothy K. Hamilton

See the rest here:
Pitt Study Sheds Light On Genetic Link Between Schizophrenia And Arthritis - 90.5 WESA

Read More...

Researchers create model of anorexia nervosa using stem cells – Medical Xpress

March 14th, 2017 4:48 pm

March 14, 2017

An international research team, led by scientists at University of California San Diego School of Medicine, has created the first cellular model of anorexia nervosa (AN), reprogramming induced pluripotent stem cells (iPSCs) derived from adolescent females with the eating disorder.

Writing in the March 14th issue of Translational Psychiatry, the scientists said the resulting AN neuronsthe disease in a dishrevealed a novel gene that appears to contribute to AN pathophysiology, buttressing the idea that AN has a strong genetic factor. The proof-of-concept approach, they said, provides a new tool to investigate the elusive and largely unknown molecular and cellular mechanisms underlying the disease.

"Anorexia is a very complicated, multifactorial neurodevelopmental disorder," said Alysson Muotri, PhD, professor in the UC San Diego School of Medicine departments of Pediatrics and Cellular and Molecular Medicine, director of the UC San Diego Stem Cell Program and a member of the Sanford Consortium for Regenerative Medicine. "It has proved to be a very difficult disease to study, let alone treat. We don't actually have good experimental models for eating disorders. In fact, there are no treatments to reverse AN symptoms."

Primarily affecting young female adolescents between ages 15 and 19, AN is characterized by distorted body image and self-imposed food restriction to the point of emaciation or death. It has the highest mortality rate among psychiatric conditions. For females between 15 and 24 years old who suffer from AN, the mortality rate associated with the illness is 12 times higher than the death rate of all other causes of death.

Though often viewed as a non-biological disorder, new research suggests 50 to 75 percent of risk for AN may be heritable; with predisposition driven primarily by genetics and not, as sometimes presumed, by vanity, poor parenting or factors related to specific groups of individuals.

But little is actually known about the molecular, cellular or genetic elements or genesis of AN. In their study, Muotri and colleagues at UC San Diego and in Brazil, Australia and Thailand, took skin cells from four females with AN and four healthy controls, generated iPSCs (stem cells with the ability to become many types of cells) from these cells and induce these iPSCs to become neurons.

(Previously, Muotri and colleagues had created stem cell-derived neuronal models of autism and Williams syndrome, a rare genetic neurological condition.)

Then they performed unbiased comprehensive whole transcriptome and pathway analyses to determine not just which genes were being expressed or activated in AN neurons, but which genes or transcripts (bits of RNA used in cellular messaging) might be associated with causing or advancing the disease process.

No predicted differences in neurotransmitter levels were observed, the researchers said, but they did note disruption in the Tachykinin receptor 1 (TACR1) gene. Tachykinins are neuropeptides or proteins expressed throughout the nervous and immune systems, where they participate in many cellular and physiological processes and have been linked to multiple diseases, including chronic inflammation, cancer, infection and affective and addictive disorders.

The scientists posit that disruption of the tachykinin system may contribute to AN before other phenotypes or observed characteristics become obvious, but said further studies employing larger patient cohorts are necessary.

"But more to the point, this work helps make that possible," said Muotri. "It's a novel technological advance in the field of eating disorders, which impacts millions of people. These findings transform our ability to study how genetic variations alter brain molecular pathways and cellular networks to change risk of ANand perhaps our ability to create new therapies."

Explore further: Stem cell-derived 'mini-brains' reveal potential drug treatment for rare disorder

More information: P D Negraes et al, Modeling anorexia nervosa: transcriptional insights from human iPSC-derived neurons, Translational Psychiatry (2017). DOI: 10.1038/tp.2017.37

Using "mini-brains" built with induced pluripotent stem cells derived from patients with a rare, but devastating, neurological disorder, researchers at University of California, San Diego School of Medicine say they have ...

Researchers at University of California, San Diego School of Medicine and Rady Children's Hospital-San Diego have created the first stem cell-derived in vitro cellular model of a rare, but devastating, neurodegenerative condition ...

With the help of mouse models, induced pluripotent stem cells (iPSCs) and the "tooth fairy," researchers at the University of California, San Diego School of Medicine have implicated a new gene in idiopathic or non-syndromic ...

In a study spanning molecular genetics, stem cells and the sciences of both brain and behavior, researchers at University of California San Diego, with colleagues at the Salk Institute of Biological Studies and elsewhere, ...

An international team of scientists led by researchers at the University of California, San Diego School of Medicine have used induced pluripotent stem cells (iPSCs) derived from patients with amyotrophic lateral sclerosis ...

Researchers at Karolinska Institutet collaborating in the large-scale Karolinska Schizophrenia Project are taking an integrative approach to unravel the disease mechanisms of schizophrenia. In the very first results now presented ...

To combat the effects of a poor diet, probiotics may be just the thing. However, surprising new research from UNSW suggests probiotics are much less effective when taken alongside a balanced diet, and could even impair certain ...

In a small-scale study of women with previously diagnosed mood disorders, Johns Hopkins researchers report that lower levels of the hormone allopregnanolone in the second trimester of pregnancy were associated with an increased ...

An international research team, led by scientists at University of California San Diego School of Medicine, has created the first cellular model of anorexia nervosa (AN), reprogramming induced pluripotent stem cells (iPSCs) ...

A dietary supplement kit, created to counter mood-altering brain changes linked to depression, virtually eliminated the "baby blues" among women in a new study at Toronto's Centre for Addiction and Mental Health (CAMH).

A study has shown thatcontrary to popular beliefolder people make riskier decisions than younger adults. Older people's generally more positive emotions make them more optimistic when gauging risks. In addition, older ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See more here:
Researchers create model of anorexia nervosa using stem cells - Medical Xpress

Read More...

‘Stem cell treatment can cure blood platelet problems’ – Business Standard

March 14th, 2017 4:48 pm

IANS | New Delhi March 14, 2017 Last Updated at 22:14 IST

Stem cell treatment, which is effective in several health conditions, including spinal problems, can also help cure extreme blood platelet problems such as thrombocytopenia, say doctors.

The medical procedure has advantage over available treatments for blood platelet problems such as corticosteroids, blood or platelet transfusions and immunoglobulins medicines.

In a case study published in International Archives of Medicne, a 25-year-old man was treated for thrombocytopenia through stem cell therapy at a city based hospital. His laboratory examinations showed that his platelet count was 0.70 m3.

The patient underwent stem cell therapy wherein he was injected with 1 mL stem cells daily through an intravenous route.

"The patient was monitored regularly for the occurrence of any reactions during the whole therapy. Platelet count increased to 1.01m3 following the treatment and there were remarkable improvements in other symptoms," said Geeta Shroff, Stem Cell Specialist, Director, Nutech Mediworld.

Shroff has also conducted successful research on patients with spinal problems, anterior cruciate ligament tear and curing them through stem cell treatment.

According to Shroff, thrombocytopenia is defined as the reduction in blood platelet count below the normal platelet count distribution (1.5m3). It is the second most common hematological disorder after anaemia and equally affects both men and women.

The decrease in the platelet number increases the bleeding and blood loss; and when coupled with other clotting disorders can lead to serious morbidity or death.

"The proliferation and differentiating ability of stem cells has made this therapy an attractive therapeutic option. Stem cell therapy are being explored as regenerative medicine for treating various diseases due to their potential to multiply, proliferate and differentiate into any cell type.

At the injured site, stem cell produce different trophic factors and reduce the cell loss, promote host regeneration, hence, restore the function," said Shroff.

--IANS

rup/lok/dg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Stem cell treatment, which is effective in several health conditions, including spinal problems, can also help cure extreme blood platelet problems such as thrombocytopenia, say doctors.

The medical procedure has advantage over available treatments for blood platelet problems such as corticosteroids, blood or platelet transfusions and immunoglobulins medicines.

In a case study published in International Archives of Medicne, a 25-year-old man was treated for thrombocytopenia through stem cell therapy at a city based hospital. His laboratory examinations showed that his platelet count was 0.70 m3.

The patient underwent stem cell therapy wherein he was injected with 1 mL stem cells daily through an intravenous route.

"The patient was monitored regularly for the occurrence of any reactions during the whole therapy. Platelet count increased to 1.01m3 following the treatment and there were remarkable improvements in other symptoms," said Geeta Shroff, Stem Cell Specialist, Director, Nutech Mediworld.

Shroff has also conducted successful research on patients with spinal problems, anterior cruciate ligament tear and curing them through stem cell treatment.

According to Shroff, thrombocytopenia is defined as the reduction in blood platelet count below the normal platelet count distribution (1.5m3). It is the second most common hematological disorder after anaemia and equally affects both men and women.

The decrease in the platelet number increases the bleeding and blood loss; and when coupled with other clotting disorders can lead to serious morbidity or death.

"The proliferation and differentiating ability of stem cells has made this therapy an attractive therapeutic option. Stem cell therapy are being explored as regenerative medicine for treating various diseases due to their potential to multiply, proliferate and differentiate into any cell type.

At the injured site, stem cell produce different trophic factors and reduce the cell loss, promote host regeneration, hence, restore the function," said Shroff.

--IANS

rup/lok/dg

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

IANS

http://bsmedia.business-standard.com/_media/bs/wap/images/bs_logo_amp.png 177 22

See the original post:
'Stem cell treatment can cure blood platelet problems' - Business Standard

Read More...

Page 1,082«..1020..1,0811,0821,0831,084..1,0901,100..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick